logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Xention Limited


USPTO Granted Patents = 22

% Expired Patents = 59.1


Forward Citations = 127

Loading Chart...
Loading Chart...

47 inventors (with patents filed for the assignee):

goldMedal David John Madge (12 out of 14 patents)

silverMedal Derek Edward John (10 out of 11 patents)

bronzeMedal John Ford (10 out of 11 patents)

4.  Basil Hartzoulakis (7 out of 11 patents)

5.  Muneto Mogi (6 out of 33 patents)

6.  Mushtaq Mulla (6 out of 7 patents)

7.  Richard John Hamlyn (6 out of 7 patents)

8.  Klaus Urbahns (6 out of 24 patents)

9.  Masaomi Tajimi (6 out of 11 patents)

10.  Yasuhiro Tsukimi (6 out of 7 patents)

11.  Takeshi Yura (6 out of 8 patents)

12.  Noriyuki Yamamoto (6 out of 9 patents)

13.  Hiroshi Fujishima (6 out of 8 patents)

14.  Toshiya Moriwaki (5 out of 12 patents)

15.  Toshio Kokubo (5 out of 6 patents)


22 patents:

1. 9290511 - Thieno-pyrimidines, useful as potassium channel inhibitors (2016-03-22),
2. 9249155 - Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia (2016-02-02),
3. 9216992 - Thieno[3,2-c]pyridine potassium channel inhibitors (2015-12-22),
4. 9073834 - Potassium channel blockers (2015-07-07),
5. 8759017 - High throughput screen (2014-06-24),
6. 8673901 - Potassium channel blockers (2014-03-18),
7. 8449825 - High throughput screen (2013-05-28),
8. 8426442 - Compounds (2013-04-23),
9. 8399481 - Compounds (2013-03-19),
10. 8372840 - Potassium channel blockers (2013-02-12),
11. 8258138 - Potassium channel blockers (2012-09-04),
12. 8193215 - Thieno[2 3-b]pyridines as potassium channel inhibitors (2012-06-05),
13. 8173841 - Tetrahydro-naphthalene derivatives (2012-05-08),
14. 8088826 - Tetrahydro-naphthalene derivatives (2012-01-03),
15. 8022076 - Substituted thieno[2,3-d]pyrimidines as potassium channel inhibitors (2011-09-20),
Company Overview
Xention Limited is a biotechnology company based in Cambridge, UK, specializing in the development of innovative therapies for cardiovascular and metabolic diseases. The organization focuses on leveraging advanced drug discovery techniques and proprietary technologies to create novel treatments that address unmet medical needs. With a commitment to scientific excellence, Xention collaborates with various partners to enhance its research capabilities and bring transformative solutions to the healthcare market.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

22 Patents

#50 in Cambridge

#814 in United Kingdom

#28,782 in the World

Cambridge, GB
Cambridge, United Kingdom

Xention Limited

Forward Citations = 127

47 inventors:

goldMedal David John Madge (12 out of 14 patents)

silverMedal Derek Edward John (10 out of 11 patents)

bronzeMedal John Ford (10 out of 11 patents)

4.  Basil Hartzoulakis (7 out of 11 patents)

5.  Muneto Mogi (6 out of 33 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xention Limited. Retrieved from https://idiyas.com/company/xention

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…